Repros Holds Meeting With FDA, Says It Is Clear FDA No Closed To Entering Secondary Hypogonadism As An Indication

Loading...
Loading...
Repros Therapeutics Inc.®
RPRX
today announced that on February 4, 2016, the Company attended a productive meeting with FDA reviewers and senior leaders to discuss resolution of issues identified during the enclomiphene NDA review. The meeting agenda covered a broad range of topics surrounding the NDA data as well as emerging Agency and expert thinking regarding the treatment of hypogonadism. The Company believes that it was clear during the meeting that the FDA is not closed to entertaining secondary hypogonadism as an indication. Conference Call Details: Time: Monday, February 8, 2016 – 5:00 PM Eastern Participant Dial-In Number (Domestic): 877-407-8629; International: 201-493-6715 It is recommended that participants call in approximately 15 minutes prior to the start time of the conference call. Replay Call Details: Conference ID Number: 13595473 Replay Dial-In (Toll Free): 877-660-6853 Replay Dial-In (International): 201-612-7415 Replay will be available through February 22, 2016.
Posted In: NewsFDAPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...